SGMTSagimet Biosciences Inc.
$8.91+21% 1Y
$8.91
$4.5552 weeks$11.16
SGMT in its own filings
Nothing in SGMT's filing record raises a hard flag: no restatement, late filing, bankruptcy or delisting notice, and no auditor change next to one. That is the common case, not a distinction.
82
Events found in the filings · across 261 filings · the record starts in 2023
- Hard flags
- none
Hard flags
- Most recent filing
- Oct 1, 2026
Most recent filing · Form 8-K
- Record starts
- Apr 20, 2023
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Change in certifying accountantpast_3y
- 2025-08-22
- SEC comment-letter activity13 occurrences
- 2025-05-07
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 1, 2026On September 30, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “Underwriters”) relating to an …Material agreement entered · Form 8-K
- Sep 30, 2026Press Release On September 30, 2026, the Company issued a press release announcing positive 52-week results from the Phase 3 ASC40-304 open-label extension clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partner Ascletis BioScience Co. Ltd. in China.Regulation FD disclosure · Form 8-K
- Aug 13, 2026On August 13, 2026, Sagimet Biosciences Inc. (the “Company”) announced that the U.S. Food and Drug Administration cleared the Investigational New Drug application and issued a “Study May Proceed” letter for the Company’s Phase 3 clinical trial of fatty acid synthase inhibitor denifanstat in moderate to severe acne.Other event · Form 8-K
- Aug 11, 2026Sagimet Biosciences Reports Second Quarter 2026 Financial Results and.Earnings release · press release
- Jul 21, 2026Forward-Looking Statements and Disclaimer This presentation contains.Regulation FD disclosure · press release
- Jun 12, 2026On June 12, 2026, Tim Walbert, a member of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”), tendered his resignation from the Board, effective as of June 12, 2026.Director or officer change · Form 8-K
- Jun 3, 2026On May 28, 2026 (the “Grant Date”), the Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) and the Board, as applicable, granted options (the “Options”) to purchase shares of the Company’s Series A common stock, par value $0.0001 …Director or officer change · Form 8-K
- May 12, 2026Reports First Quarter 2026 Financial Results and Provides Corporate Updates.Earnings release · press release
- Apr 28, 2026On April 27, 2026, Sagimet Biosciences Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “Underwriters”) relating to an …Material agreement entered · Form 8-K
- Apr 27, 2026Targeting MetabolicDysfunction.Regulation FD disclosure · press release
- Apr 27, 2026On April 27, 2026, the Company issued a press release announcing certain strategic and corporate updates.Earnings release · Form 8-K
- Apr 21, 2026Retirement of Chief Medical Officer On April 20, 2026, Eduardo Martins, M.D., D.Phil. provided notice to Sagimet Biosciences, Inc. (the “Company”) of his retirement from his role as Chief Medical Officer of the Company, effective as of April 20, 2026.Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…